The fast-paced future of cell and gene therapies
November 3, 2022 | CRISPR, Market Access, Medical Communications, Policy, cell and gene, cell therapy, gene therapy, patient engagement, precision medicine, rare disease
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Cell and gene therapies represent a paradigm shift in the development of pharmaceutical products.
Not only do these treatments often promise to cure disease, they also represent an evolution in the manufacture and delivery of products. As a result, cell and gene therapies are synonymous with complexity.
Manufacturers developing cell and gene therapies face a steeper climb to commercialization compared with traditional biopharmaceutical products. While there is significant innovation in this space, few cell and gene therapies reach the market.
Additionally, those that do have been marred by supply chain and manufacturing challenges, along with healthcare infrastructure barriers, including a lack of treatment sites for administering therapies.
These factors affect the scalability of these products and the patient and healthcare professional experience. Add to this a fast-paced global policy and regulatory landscape in which policymakers and regulators struggle to upskill fast enough to keep up with the evolving high science. Payers require more support than ever to understand the novel data and make decisions regarding these therapies.
Patients and healthcare professionals alike are entranced by the promise of the treatments but require support in understanding the risks and benefits of novel cell and gene therapies.
Understanding the barriers and risks early in drug development is paramount for ensuring these therapies deliver on their promises for patients.
Drawing on our experience working with biopharmaceutical innovators on the commercialization and launch of cell and gene therapies, we have developed a series of articles on the evolving landscape, which we present in this publication.
Read on to learn about:
- An interview with Professor Francesco Dazzi, Medical Lead Cell Therapy, BioPharmaceuticals R&D at AstraZeneca, on the company’s novel cell therapy pipeline for chronic diseases
- Patient and market access insights on leveraging CRISPR technology for hematologic diseases
- The evolving policy and regulatory landscape for cell and gene therapies
- Trends shaping the future of personalized medicine
- Steps for communicating the complex science to a variety of stakeholders
This content was provided by Avalere Health
Company Details
Latest Content from Avalere Health
Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs
Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.
Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient
As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.
Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities
As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.
Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies
Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the…
Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer
Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts…
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of…
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech…
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.